YOU ARE ENTERING HCP CONTENT ONLY

Please note you are entering now content intended only for Healthcare Professionals.

Are you a HCP?

YES I AM A HCP NO I AM NOT A HCP
placeUnited Kingdom
Contact & Support
Medtronic / Clinical Solutions / Barrett's Esophagus

The power
to make the difference

The power to eradicate Barrett's esophagus† is in your hands.1

Download the Barrx RFA value dossier

Reduce the risk of progression of Barrett's Esophagus (BE) with proven treatment2

Treatment with radiofrequency ablation (RFA) can lead to significantly improved outcomes for patients with Barrett's Esophagus (BE), including:

  • Up to 94%* reduction in the relative risk of disease progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC).1
  • RFA can reduce absolute risk of progression from confirmed LGD to HGD/EAC by 25% compared to surveillance (NNT=4).1

Download the product catalogue Watch the online webinar series

Stages of the disease

Nondysplastic Barrett's esophagus
Low-grade dysplasia
High-grade dysplasia
Esophageal adenocarcinoma

Clinical studies have demonstrated the safety and efficacy of RFA for treating all grades of Barrett's esophagus.2,3

BarrxTM RFA is a proven effective & durable therapy4

Many publications demonstrate the efficacy of BarrxTM RFA for the treatment of Barrett's esophagus

  • Multiple trials have shown that treatment with RFA in dysplastic BE patients is safe. RFA is associated with low rates of esophageal strictures and low incidence of buried intestinal metaplasia5,6
  • BarrxTM RFA is effective in patients with confirmed Low-Grade Dysplasia and High-Grade Dysplasia without visible abnormalities7
  • BarrxTM RFA results in complete eradication of dysplasia in 80-90% of patients with BE8

Download the Barrx RFA Value dossier

A safe and effective treatment for Barrett's Esophagus

  • Endoscopic ablation therapy has proved to be more effective than surveillance.1
  • Radiofrequency ablation (RFA) has been shown to be a good option for the treatment of patients with LGD and HGD with low rate of complications and good cost-effective results.9
  • Moreover, the use of RFA for the treatment of patients with confirmed LGD has shown a significant reduction in progression to HGD and EAC in one randomized trial.1
  • The proprietary technology in Barrx™ radiofrequency ablation systems is designed to remove the Barrett’s epithelium without significant injury to the underlying tissue.10
  • ESGE guidelines support the use of radiofrequency ablation in the treatment guidelines for dysplastic Barrett's esophagus.11

What experts say

Dr. Komanduri and Dr. Infantalino discuss the efficacy of radiofrequency ablation in endoscopic therapy at eradicating disease, but also insuring a durable and long-lasting treatment.

BarrxTM Radiofrequency Ablation System

The Barrx™ radiofrequency ablation system includes the Barrx™ flex RFA energy generator and a family of ablation catheters which are designed to precisely control depth and uniformity of GI tissue ablation.9

Learn more about our product solutions

Clinical Education

Watch the online Barrx RFA webinar series.

Watch the webinars
Harry Corder's Story
Juan Carlos's Story
Adam Grover's Story

Interested in learning more?

Talk to a Medtronic sales representative about how the Barrx™ radiofrequency ablation system can treat Barrett’s esophagus and help reduce risk for patients who may be intermediate or at high risk for progression to HGD or EAC.

Contact us

Barrx™ radiofrequency ablation system


Indications: The Barrx™ Channel RFA Endoscopic Catheter, Barrx™ 90, Barrx™ Ultra Long, and Barrx™ 60 RFA Focal Catheters and Barrx™ 360 Express RFA Balloon Catheter are indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract, including but not limited to, Barrett’s esophagus and esophageal squamous cell neoplasia, defined as moderate grade intra-epithelial neoplasia (MGIN), high grade intra-epithelial neoplasia (HGIN), and/or early squamous cell carcinoma (SCC) of the esophagus limited to the lamina propria (i.e., T1m2).

Contraindications: Contraindications include pregnancy, prior radiation therapy to the esophagus, esophageal varices at risk for bleeding, prior Heller myotomy, and eosinophilic esophagitis.

Risk Information: The following are transient side effects that may be expected after treatment: chest pain, difficulty swallowing, painful swallowing, throat pain, and/or fever. Potential complications include mucosal laceration, minor or major bleeding, endoscopic clipping to manage mucosal laceration or bleeding, perforation of the stomach, oesophagus or pharynx, surgery to manage perforation, esophageal stricture, endoscopic dilation to manage stricture, pleural effusion, transfusion secondary to major bleeding, cardiac arrhythmia, aspiration, infection, and death.

References

† Complete eradication occurred in 92.6% of cases.
* 94% is the calculated relative risk reduction [ (26-1.5)/26] = 25/26 *100. From [25.0% (1.5%for ablation vs 26.5%for control; 95%CI, 14.1%-35.9%; P < .001]
 
  1. Phoa KN, et al. Radiofrequency ablation vs. endoscopic surveillance for patients with Barrett’s esophagus and low-grade dysplasia: A randomized clinical trial. JAMA. 2014 Mar 26;311(12):1209–17. 
  2. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009;360:2277–88. 
  3. Phoa KN, Pouw RE, van Vilsteren FG, et al. Remission of Barrett’s esophagus with early neoplasia 5 years after radiofrequency ablation  with endoscopic resection: A Netherlands cohort study. Gastroenterology. 2013;145:96–104. 
  4. Halland.M. Recent developments in pathogenesis, diagnosis and therapy of Barrett's Esophagus. World Journal of Gastroenterology 2015 June 7; 21(21): 6479-6490.
  5. Shaheen NJ al. Radiofrequency Ablation in Barrett’s Esophagus with Dysplasia. New England Journal of Medicine. 2009  May;360(22):2277-2288 
  6. Hathorn et al. Predictors of complications from radiofrequency ablation during treatment of Barrett’s esophagus: results from the U.S.  RFA registry. Gastrointestinal Endoscopy 2014;79(5), AB152-153. 2014 DDW Abstracts 
  7. Whiteman DC, et al. Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma. J Gastroenterol Hepatol 2015; 30: 804-20. 
  8. Phoa KN. et al. Multimodality endoscopic radication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut 2015; doi 10.1136/gutjnl-2015-309298. 
  9. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG Clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2015; 
  10. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endoscopy. 2008;68:867–876.
  11. Weusten Bas et al. ESGE Guidelines. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017.